Gilead reported revenues of $6.67 billion in the last reported quarter, representing a year-over-year change of -0.3%. EPS of $1.81 for the same period compares with -$1.32 a year ago.

In the latest trading session, Gilead Sciences (GILD) closed at $109.06, marking a -2.7% move from the previous day. This change lagged the S&P 500's daily loss of 0.4%. Meanwhile, the Dow lost 0. ...

In the latest trading session, Gilead Sciences (GILD) closed at $105.93, marking a -1.18% move from the previous day. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31% ...

Gilead Sciences, Inc. GILD announced that the FDA has placed a clinical hold on studies on pipeline candidates, GS-1720 and/or GS-4182, for the treatment of HIV. GS-1720 is an investigational ...

Gilead Sciences is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for GILD's full-year earnings has moved 0.7% higher within the past quarter.

(RTTNews) - Gilead Sciences Inc. (GILD) announced that the U.S. Food and Drug Administration has approved Yeztugo (lenacapavir)-the company's injectable HIV-1 capsid inhibitor-as pre-exposure ...

Explore the exciting world of Gilead Sciences (NASDAQ: GILD) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options begin trading this week, for the February 2026 expiration. One of the key inputs that goes into the price an option buyer is willing ...

In Wednesday trading, Gilead Sciences Inc shares are currently down about 2.6%, CONMED Corp shares are up about 0.6%, and Thermo Fisher Scientific Inc shares are up about 1.5% on the day.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Gilead Sciences (NASDAQ:GILD) and its peers.

On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: GILD) took some hits on Tuesday. Investors traded it down by more than ...

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the August 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ...